A health worker shows a dose of Chinese Sinopharm Covid-19 vaccine at a vaccination center in the Jordanian capital, Amman, on January 13, 2021.
Khalil Mazraawi | AFP | Getty Images
BEIJING – Sinopharm, a state giant in the development of China’s coronavirus vaccine, announced that its president left the council on Tuesday.
The company cited personal reasons for Li Zhiming’s resignation, according to a Hong Kong-listed company file. Li Hui, director and member of the audit committee of Sinopharm’s subsidiary, China National Medicines Corp., also resigned on Tuesday for personal reasons, according to a separate file.
In late December, Chinese authorities approved a vaccine developed by a Beijing-based subsidiary of Sinopharm for its general launch. The company said the vaccine had an effectiveness of 79.34% after a phase three test, according to state media.
In early December, the UAE said the vaccine was 86% effective.
There was no direct indication that the waivers occurred as a result of vaccine-related work. The company did not immediately respond to CNBC’s request for email feedback.
Different countries have published several results on the effectiveness of a coronavirus vaccine from another Chinese company, Sinovac.
A WHO team is working with Covid-19 vaccine producers from Chinese pharmaceutical companies Sinovac and Sinopharm “to assess compliance with international quality manufacturing practices before the list of possible emergency uses by the WHO, ”WHO Director-General Tedros Adhanom Ghebreyesus said earlier this week. .